TP53 and B-cell chronic lymphocytic leukemia: The fludarabine-cyclophosphamide-rituximab (FCR) regimen is a standard treatment option for medically fit CLL patients, excepting those who carry aberrations of the TP53 gene [mutation and/or del(17p)] [6–9].